SEC Form 4 · accession 0002048500-26-000012
Beta Bionics, Inc. · BBNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mike Mensinger
Officer — Chief Product Officer
Period of report
Sep 2, 2026
Accepted (ET)
Sep 3, 2026 · 6:15 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001674632
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 2, 2026 | S | 4,375 | $19.1131 | D | 180,040 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.
- F2The weighted average sale price for the transaction reported was $19.1131 and the range of prices were between $18.89 and $19.545. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.